Next Article in Journal
Evaluation of Biochemical and Oxidative Stress Markers in the Early Stages of Rheumatoid Arthritis in a Comparative Study of Two Different Therapeutic Approaches
Previous Article in Journal
Highly Oxygenated Cyclobutane Ring in Biomolecules: Insights into Structure and Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Oxygen
Volume 4
Issue 2
10.3390/oxygen4020013
oxygen-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities

by
Sydney L. Olson
1,
Razeen J. Akbar
2,
Adrianna Gorniak
1,
Laura I. Fuhr
1 and
Mostafa A. Borahay
1,*
1
Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
2
Temple University, Philadelphia, PA 19122, USA
*
Author to whom correspondence should be addressed.
Oxygen 2024, 4(2), 236-252; https://doi.org/10.3390/oxygen4020013
Submission received: 1 April 2024 / Revised: 20 May 2024 / Accepted: 23 May 2024 / Published: 28 May 2024
Browse Figures
Versions Notes

Abstract

:
Uterine fibroids are the most common tumors in females, affecting up to 70% of women worldwide, yet targeted therapeutic options are limited. Oxidative stress has recently surfaced as a key driver of fibroid pathogenesis and provides insights into hypoxia-induced cell transformation, extracellular matrix pathophysiology, hypoxic cell signaling cascades, and uterine biology. Hypoxia drives fibroid tumorigenesis through (1) promoting myometrial stem cell proliferation, (2) causing DNA damage propelling the transformation of stem cells to tumor-initiating cells, and (3) driving excess extracellular matrix (ECM) production. Common fibroid-associated DNA mutations include MED12 mutations, HMGA2 overexpression, and fumarate hydratase loss of function. Evidence suggests an interaction between hypoxia signaling and these mutations. Fibroid development and growth are promoted by hypoxia-triggered cell signaling via various pathways including HIF-1, TGFβ, and Wnt/β-catenin. Fibroid-associated hypoxia persists due to antioxidant imbalance, ECM accumulation, and growth beyond adequate vascular supply. Current clinically available fibroid treatments do not take advantage of hypoxia-targeting therapies. A growing number of pre-clinical and clinical studies identify ROS inhibitors, anti-HIF-1 agents, Wnt/β-catenin inhibition, and TGFβ cascade inhibitors as agents that may reduce fibroid development and growth through targeting hypoxia.

1. Introduction

Uterine fibroids, also known as leiomyomas, are the most common tumors in females, affecting up to 70% of women worldwide with increasing incidence [1,2]. Women with fibroids have significantly increased rates of infertility [3], hypertension [4], and depression [5] compared to controls. Annual costs of fibroids in the United States range from USD 4–9 billion for direct care and up to an additional USD 17 billion for lost work-hour costs [6]. Medical treatments are limited for preventing fibroid development and growth and many people will require surgical intervention in the form of myomectomy or hysterectomy. While there is a growing body of knowledge on the pathogenesis of fibroids, many of the mechanisms remain elusive, thereby limiting the ability to develop targeted therapies. In the past decade, oxidative stress has surfaced as a key driver of fibroid pathogenesis [7]. While multiple pathways contribute to developing oxidative stress, this review will focus on hypoxia and summarize the evidence, mechanisms, and emerging hypoxia-targeting treatments in fibroids.

2. Hypoxia and Oxidative Stress

Oxidation–reduction (redox) reactions are fundamental biochemical processes that contribute to the homeostasis of living organisms. The concept of ‘oxidative stress’, initially described as an imbalance of antioxidants and oxidants, more specifically refers to a slight or severe elevation in reactive oxygen species (ROS) concentrations [8]. Specific types of ROS include any radical or non-radical derivatives of molecular oxygen (O2); predominantly, superoxide (O2•−), hydrogen peroxide (H2O2), hydroxyl radical (•OH), ozone (O3), and O2 itself [9]. A disturbance in redox homeostasis, such as excessive ROS levels, can contribute to biochemical damage within cells and the development of disease [10].
Hypoxia, characterized by low oxygen levels in a living system, results in an influx of ROS by affecting complexes I, II, and III of the mitochondrial Electron Transport Chain (ETC) [11], thereby contributing to oxidative stress [12]. Under hypoxic pressure, cells activate a series of pathways to counteract the sudden decrease in oxygen, including hypoxia-inducible factor (HIF), energy metabolic pathways, cell stress pathways, and autophagy [13]. In chronically hypoxic environments, many cell types deploy compensatory mechanisms to promote adaptation and survival such as angiogenesis, anaerobic respiration, and glucose metabolism.
Hypoxia is implicated as a driving force in both benign and malignant conditions including atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, Alzheimer’s disease, and numerous cancers [10]. Oxidative stress both promotes tumorigenesis via DNA damage and malignant cellular transformation and tends to create cells that can persist in hypoxic environments due to metabolic dysregulation; thus creating a self-propelling cycle of hypoxia and atypical growth [14].

3. Evidence of Hypoxia in Uterine Fibroids

The hypothesis of hypoxia association with menstrual cycling was first proposed in the 1940s by Markee et al., who observed vasoconstriction of spiral arteries in transplanted endometrial explants following progesterone withdrawal in a Rhesus macaque model of menstruation [15]. Since then, these results have also been supported by mouse models of simulated menses that identified transient hypoxia in endometrial tissue during the menstrual phase of the menstrual cycle [16,17]. Additionally, specialized dynamic contrast-enhanced MRI protocols have been used to quantify tissue hypoxia in many organ systems, with a recent study identifying temporary endometrial hypoxia at the time of menstruation in women with normal cycles [18]. In addition to spiral artery constriction, small contractions of the myometrium during menses are also hypothesized to contribute to hypoxia, which may initiate local hypoxic-triggered cell signaling to facilitate cessation of menses by stabilizing the endometrium [16,19].
The physiologic hypoxia of the menstrual cycle is hypothesized to be a contributor to pathologic hypoxia seen in the development and growth of fibroids. Fibroid development is multifactorial with influence from local and systemic inflammation, endocrine disrupting chemicals, altered sex hormone signaling, genetic predispositions, vitamin D deficiency, and lifestyle exposures. Many of these factors contribute to oxidative stress and result in hypoxic cellular environments that are persistent beyond the menstrual cycle [20].
Based on the invasive nature of in vivo sampling, much of the evidence for hypoxia in fibroids depends on measurements of well-established cell signaling responses to hypoxia or ex vivo pathologic analysis. One of the few in vivo human studies used intraoperative polarographic needle electrode measurements to measure the partial pressure of oxygen in leiomyoma compared to normal myometrium in women undergoing hysterectomy and found median partial pressure of oxygen of 1 mmHg (range 0–5 mmHg) in leiomyomas compared to 9 mmHg (range 5–20 mmHg, p < 0.0001) in surrounding myometrial tissue [21]. This direct measurement supports the many studies that have found various proteins associated with hypoxic states to be significantly altered in patients with fibroids including HIF-1 [22,23,24], ET-1 [25], ALDOA, ENO1, LDHA, VEGFA, PFKFB3, and SLC2A1 [23], VEGF-A, ADM [24], COX-2 [22], catalase [26], and additional genes well summarized by Fedotova et al. [27].

4. Hypoxia and the Development of Fibroids

Hypoxia is involved in key events that contribute to the development of fibroids, as well as in signaling that promotes additional growth and persistence of cells. While the transformation and growth of fibroids exist in a continuous spectrum, the following section will focus on hypoxia, contributing to inciting events in fibroid development (Figure 1) [19,28,29,30].

4.1. Uterine Fibroid Stem Cells

Myometrial stem cells (MSCs) have been isolated from normal myometrial tissue and are characterized by a lack of myometrial cell markers, expression of CD44(Stro-1) [31], and ability to proliferate and differentiate into mature myometrial cells, osteocytes, and adipocytes [28]. These cells contribute to hypertrophy and hyperplasia during pregnancy as well as oxytocin receptor expression [28]. Growing evidence supports MSCs as the origin cell for leiomyomas, with the acquisition of cellular mutations (discussed in the next section) that reprogram the cells into tumor-initiating stem cells (TICs), resulting in a terminally differentiated subset of monoclonal cells that give rise to leiomyomas [32,33].
Multiple lineages of stem cells (mesenchymal, neural, and hematopoietic) have been shown to preferentially reside in hypoxic niche environments [34]. One hypothesis is that relative hypoxia allows stem cells to avoid oxidative damage and growth pressure, thereby maintaining pluripotency. Specifically, myometrial stem cells have been shown to require hypoxic environments in vitro to proliferate [28]. This finding supports the theory that uterine environments with greater degrees or persistence of hypoxia enable greater MSC proliferation, thereby increasing the possibility of MSC transformation into a TIC. This hypothesis is further supported by the finding that women with fibroids had significantly larger populations of MSCs in their myometrium than women without fibroids [35].

4.2. Genetic Mutations

Uterine fibroids, like other tumors, undergo genetic variations through DNA mutation. Mechanisms of ROS-inducing DNA damage include single and double-stranded DNA breaks, nitrogen base damages, mismatched bases, and base degradation [29,30,36]; these well-studied mechanisms of damage paired with increased MSC activity are hypothesized to contribute to genesis events in fibroid formation [37]. Recent studies have identified four recurrent driver gene mutations that are suspected to occur at the onset of tumorigenesis (Figure 2): gain of function mutations in the mediator of RNA polymerase II transcription, subunit 12 homolog (MED12), high mobility group AT-hook 2 (HMGA2) rearrangements, biallelic inactivation of fumarate hydratase (FH), and deletions of collagen, type 4, alpha 5/6 (COL4A5/COL4A6) [38].

4.2.1. MED12

MED12 is the most prevalent among these studied mutations with whole-genome sequencing, with MED12 mutations found in up to 70% of uterine fibroids (Figure 2A) [7,39]. The MED12 gene, located on chromosome Xq13.1, expresses missense gain of function mutations in leiomyomas, which typically occur in exon 2 [38] or rarely in the intron-2-exon-2 junction [37]. These mutations play a key role in uterine fibroid tumorigenesis [40] by altering the mediator complex responsible for activating cyclin-dependent kinase 8 (CDK8) and regulating mediator-polymerase II interactions during initiation of gene transcription [37,41,42]. The exact biologic mechanisms altered by MED12 mutations are an active field of study that may involve aberrant R-loop function and altered replication fork dynamics, resulting in replication stress [43,44]. Common cellular outcomes of the MED12 mutation include increased ECM deposition [45] and estrogen responsiveness, decreased autophagy, and aberrant down-stream cell signaling via Wnt/β-catenin and mTOR [46] compared to normal myometrial cells [47]. Additionally, MED12 mutations are associated with a greater number of individual fibroids and subserousal fibroids [48], and are more common in black women compared to white and Asian women [49]. Within patients, individual fibroids are thought to occur independently, as evidenced by unique mutation burdens, with some patients harboring up to five different MED12 mutations across five different fibroids [50].

4.2.2. HMGA2

HMGA2 is part of the high mobility group family of proteins comprised nonhistone chromatin-associated molecules that bind to AT-rich DNA sequences to maintain chromatin structure and regulate transcription (Figure 2B) [51]. In leiomyomas, HMGA2 mutations are most commonly caused by the chromosomal rearrangement of 12q15, leading to an overexpression of the protein and contributing to an individual mutation frequency of around 10–20% [38]. Though previously believed to be mutually exclusive driver gene mutations, HMGA2- and MED12-mutated uterine fibroids have been frequently reported in tandem in recent studies [52]. Downstream effects of HMGA2 include the upregulation of angiogenic proteins [53] and this signaling tends to result in larger solitary tumors compared to other mutation burdens [54]. The most studied downstream targets of increased HMGA2 activity are proto-oncogene pleomorphic adenoma gene 1 (PLAG1), insulin-like growth factor-2 (IGF2) [55], fibroblast growth factor 2 (FGF2) [56], epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF) [53].

4.2.3. Fumarate Hydratase

Fumarate hydratase inactivation in both alleles is seen in 1–2% of leiomyomas (Figure 2C). Fumarate hydratase converts fumarate to malate as one step in the tricarboxylic acid (TCA) cycle of aerobic metabolism [57]. Deficiencies in FH lead to a buildup of fumarate, which has been shown to directly bind the antioxidant glutathione and thereby contribute to an increase in ROS [58]. FH deficiency occurs both in sporadic mutations within leiomyomas [59] as well as somatic mutations in hereditary leiomyomatosis and renal cell carcinoma (HLRCC), which is characterized by heterozygous germline mutations in FH [60]. The identification of FH-deficient fibroids is conducted at the time of pathologic analysis and growing research is being conducted to characterize the histologic features of this unique fibroid subset [61]. FH-deficient leiomyomas have been uniquely shown to activate nuclear factor erythroid 2-related factor 2 (NRF2) target genes based on the excess of fumarate. NRF2 is an anti-inflammatory transcription factor that regulates multiple pathways involved in cells’ response to oxidant signaling and damage [62]. NRF2 is pathologically upregulated by many cancers as a means of promoting resistance to oxidative damage and promoting growth [63]; the exact role of NRF2 in fibroids requires further investigation but likely follows this pathway.

4.2.4. Collagen

Collagen (COL4A5/COL4A6) deletions occur at a frequency of less than 1% but are observed across fibroid samples [38]. Type IV collagens, such as COL4A5 and COL4A6, are major structural components of basement membranes (BMs) that separate epithelial cells from endothelial cells [64]. The COL4A5 gene, located on chromosome Xq22 and head-to-head with the COL4A6 gene, encodes the α5 chain of type IV collagen2, which forms a heterotrimer with α3, α4, and α5 chains [65]. The COL4A5 α5 chain is largely responsible for the promotion of tumor angiogenesis and cell proliferation in lung cancer through non-integrin collagen receptor DDR1-mediated ERK activation [64]. Similarly, the COL4A6 gene encodes the α6 chain of type IV collagen, providing structural support in the BMs of the heart, aorta, esophagus, and bladder [66]. According to studies conducted by Mehine and colleagues, alterations in the COL4A5/COL4A6 locus arose in multiple uterine leiomyoma samples through chromothripsis, a series of complex chromosomal rearrangements associated with aggressive cancer types and tumors, such as leiomyomas [67]. These studies further indicated an association between elevated IRS4 expression and deletions in COL4A5/COL4A6 [67]. Located adjacent to COL4A5, the IRS4 gene encodes insulin-receptor substrate 4, a downstream effector of insulin-like growth factor I known for its role in uterine fibroid development [67]. COL4A5/COL4A6 mutated leiomyomas have also been shown to have significantly elevated prolactin and associated genes in genome-wide association studies (GWAS) [55].

4.3. Extracellular Matrix

Normal myometrium is composed of parallel smooth muscle cells and interfascicular collagens that form a basketweave appearance on histology, whereas fibroids have disordered proliferation and significantly increased deposition of collagens, fibronectin, laminins, and proteoglycans, creating a fibrotic stromal whorl matrix [19,68]. Fibroid growth has been described in four phases: (1) proliferation of myocytes, (2) proliferation of myocytes and synthesis of collagen, (3) proliferation, synthesis of collagen, and early senescence, and (4) involution [19]. In phase 1, fibroids do not have a significant concentration of collage in their matrix and by phase 4, involution fibroids are >50% collagen. In phases 3 and 4, fibroids become removed from native vascular supplies and rates of angiogenesis fail to keep up with ECM deposition, creating interstitial ischemia [69]. Additionally, fibroblast cells in the ECM secrete auto- and paracrine signals that further promote the growth of leiomyoma smooth muscle cells and collagen production [70]. Larger fibroids have higher relative proportions of fibroblast cells than smaller fibroids, suggesting their key role in driving growth through ECM expansion [71]. Furthermore, once formed, uterine fibroids are surrounded by a pseudo-capsule composed of areolar muscle fiber that separates the internal monoclonal smooth muscle cells and excess extracellular matrix from the normal myometrium and uterine circulatory system [72,73]. Fibroid myocytes then undergo inanosis, a slow cellular death progressing over days to months due to lack of nutrients, leaving behind myocyte tombstones visible via electron microscopy [19].
Hypoxia again acts in a self-promoting cycle of driving cell signals that result in excessive ECM deposition and the dense ECM furthering the hypoxic environment [74,75]. ROS are known to increase the activity of lysyl oxidase (LOX) [76], an enzyme that creates intra- and inter-molecular cross-links on collagen in the ECM. In fibroids, LOX expression is increased and drives excess lysine residues on collagen, creating additional hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-links resulting in a stiff ECM [77]. Transforming growth factor (TGF) β signaling (one of the pathways to be discussed below) is activated by hypoxia and TGFβ3 has been shown to increase mRNA expression of key ECM components including collagen 1A1, connective tissue growth factor, and fibronectin [78,79] as well as decrease the expression of enzymes involved in matrix resorption matrix metalloproteinase 2 and 11 [79]. In addition to being a physical barrier slowing oxygen diffusion, the dense ECM increases the stiffness of the myometrium and mechanotransduction transmits this biomechanical stress throughout the uterus [20]. Mechanotransduction, the conversion of physical stretch signals into biological signals, is hypothesized to contribute to rates of subfertility seen in patients with fibroids due to the propagation of signals that disrupt endometrial proliferation [80].

5. Hypoxia-Associated Cell Signaling in Uterine Fibroids

5.1. HIF

Production of transcription factor hypoxia-inducible factor-1 (HIF-1) is one of the most common signaling mechanisms for hypoxia seen throughout the body [81]. HIF-1 consists of two subunits, alpha and beta, located in the cells’ cytoplasm and nucleus, respectively. HIF-1α activity is dependent on cellular oxygen status, while HIF-1β is constitutively expressed. In conditions with normal oxygen, HIF-1α activity is regulated by prolyl-4-hydroxylases (PHD) and factors inhibiting HIF (FIH). Both PHDs and FIHs require oxygen; thus, in hypoxic conditions, these inhibiting factors are unfunctional and the HIF-1α subunit can translocate into the cells’ nucleus and form a heterodimeric complex with the beta subunit and modulate the expression of HIF-responsive genes.
HIF-1 induces more than 100 target genes, which are important in hypoxic adaptive pathways, such as angiogenesis, oxygen homeostasis, and cell proliferation [23,82]. In a study performed by Miyashita-Ishiwata et al., the researchers found that, under hypoxic conditions, HIF-1 was expressed in both leiomyoma and normal myometrium; however, secretion of HIF-1 target proteins, such as VEGF-A, ET-1, and ADM, was found only in leiomyomas [24]. This suggests that uterine fibroids have developed an adaptive response to hypoxia. Similarly, Ishikawa et. al found six HIF-1 target genes (ALDOA, ENO1, LDHA, VEGFA, PFKB3, and SLC2A1) that were significantly upregulated in uterine fibroids [23]. Of these target genes, vascular endothelial growth factor (VEGF-A), adrenomedullin (ADM), and endothelin 1 (ET-1) are involved in angiogenesis, allowing the fibroid to divert nutrients and oxygen and continue to grow [23,24]. Aldolase A (ALDOA), lactate dehydrogenase A (LDHA), pyruvate kinase M (PKM2), and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) are HIF-response targets that regulate efficient anaerobic cell metabolism via glucose transportation and glycolysis [23]. Additional GWAS studies of fibroid samples have shown significant enrichment of genes related to angiogenesis, vascular tone, pro-growth, and anti-apoptosis [27].

5.2. Wnt/β-Catenin

The Wingless-related integration site/β-catenin (Wnt/β-catenin) pathway is imperative to the growth, development, and proliferation of uterine fibroid cells [83]. Wnt, a glycoprotein secreted by cells into the ECM, activates the Frizzled family membrane receptor, initiating a signal cascade that results in inhibition of β-catenin degradation, a transcriptional regulator of downstream target genes [84,85]. Ultimately, activation of Wnt in fibroids leads to increased concentrations of β-catenin in the nucleus where it binds to T-cell factor (TCF) and lymphocyte enhancement factor (LEF) transcription factors, resulting in the expression of target genes involved in cell differentiation, survival, and neoplasia [86]. Overexpression of various Wnt ligands activates the Wnt/β-catenin signaling pathway and promotes the formation and growth of uterine fibroids (Wnt 4 and Wnt 5A) and leiomyoma stem cells (Wnt 11 and Wnt 16), respectively [83].
Target effects upregulated in fibroids by signaling through Wnt/β-catenin include estrogen, progesterone, TGFβ, PI3K/Akt/mTOR, Ras/Raf/MEK/ERK, IGF, Hippo, and Notch signaling [83]. Mutations in MED12 are hypothesized to contribute to increased Wnt4 and β-catenin protein levels, contributing to dysregulated signaling through Wnt/β-catenin [46]. The excess activation of cell growth processes through Wnt may further hypoxia and the excess ROS levels that drive DNA damage, tumor formation, and progression [87].

5.3. TGFβ

In addition to HIF and Wnt pathways, transforming growth factor β (TGFβ) is a well-characterized signaling pathway used by many cell and tumor types driving proliferation. TGFβ, present in three main isoforms (TGF-β1, TGF-β2, and TGF-β3), is a polypeptide secreted into the ECM. Signaling through the TGFβ receptor results in the phosphorylation of transcription factor SMAD3, which allows it to translocate to the nucleus and upregulate target genes [88].
Overexpression of TGFβ in both uterine fibroids and the myometrium contributes to growth and symptom progression; in particular, the TGFβ3 isoform remains present in uterine fibroid tissue with concentrations nearly five times higher than that of the normal myometrium [89,90,91]. Hypoxia has been shown to directly induce excess TGFβ3 expression in fibroids [92]. Downstream targets of TGFβ3/SMAD3 signaling transcribed in fibroids include collagen, plasminogen activator inhibitor (PAI) 1, and connective tissue growth factor (CTGF) [93]. TGFβ3 also drove increased expression of NADPH oxidase 4 (NOX4), a producer of ROS superoxide and H2O2, further driving local hypoxia [92,94]. TGFβ also induces fibronectin and glycosaminoglycan expression [91] in leiomyoma cells, contributing to the dense ECM that further drives hypoxia [95].

5.4. Antioxidant Signaling

In addition to pro-growth signals in the presence of hypoxia, the ability of fibroid cells to combat ROS is impaired in various pathways. Two common antioxidant enzymes, superoxide dismutase-3 (SOD-3) and catalase, have been shown to have significantly reduced activity and mRNA in leiomyoma cells compared to normal myometrial cells [26]. SOD catalyzes the dismutation reaction of superoxide ion (O2●−) to H2O2 and catalase scavenges H2O2, catalyzing decomposition into O2 and H2O. SOD is primarily secreted as a plasma protein and acts in the extracellular space; decreased expression in fibroids likely furthers the hypoxic environment created by the dense ECM [96]. An additional repressed antioxidant pathway is the impairment of manganese superoxide dismutase (MnSOD) activity via acetylation, which is seen in a majority of immortalized leiomyoma cell lines with a significantly reduced function compared to patient-matched myometrial cells [97].

6. Hypoxia as a Therapeutic Target in Uterine Fibroids

Fibroids can vary in size and location and are classified by the FIGO Leiomyoma Subclassification System. Due to their diverse presentation, symptoms vary with abnormal uterine bleeding being the most common symptom. Other presenting symptoms are collectively referred to as bulk symptoms with potential impact on the genitourinary and gastrointestinal tract as well as pelvic pressure [98,99]. Currently, fibroids leading to bothersome symptoms are managed with expectant, medical, procedural, or surgical intervention with the primary goal of reducing symptom burden. While hysterectomy is the definitive treatment option for uterine fibroids and is the leading indication for hysterectomy [100], many patients opt for alternative management options to avoid surgical intervention due to patient preference, surgical candidacy, or desire for future fertility.
Currently, approved therapeutic options in the United States include medical treatment for bleeding symptoms with gonadotropin hormone-releasing hormone (GnRH) antagonists, levonorgestrel-releasing intrauterine devices, tranexamic acid, or contraceptive agents. Additionally, GnRH agonists and selective progesterone receptor modulators can be utilized for both bleeding and bulk symptom management. FDA-approved procedures include uterine artery embolization, radiofrequency ablation, MRI-guided focused ultrasound, and endometrial ablation. Surgical interventions include the removal of some or all fibroids via hysteroscopic or abdominal myomectomy or removal of the uterus—hysterectomy. There are currently no FDA-approved medications that directly target the hypoxia pathway to treat uterine fibroids. However, as there is a growing body of evidence that hypoxia plays a significant role in the pathogenesis of leiomyomas, this represents an area for the potential development of novel therapeutics (Figure 3).

6.1. Antioxidant Therapies

A variety of agents targeting oxidative damage have shown benefit in pre-clinical and population-level studies of fibroid growth. Diets high in antioxidants such as vitamin A, carotenoids, lycopene, vitamin E, and green tea extracts are associated with decreased risk of uterine fibroid development and there is some evidence that dietary changes can show benefits in reducing symptoms in fibroid patients [101,102]. Statins have also been shown to be effective in limiting fibroid cell proliferation, possibly via attenuation of oxidative stress, and this is an area of ongoing translational and clinical research [103]. There is ongoing research into the utilization of N-acetyl cysteine in fibroid management, with clinical trials suggesting efficacy in reducing tumor volume, which is hypothesized to be secondary to effects on free radical species [104].

6.2. HIF-1 Inhibition

HIF-1 inhibitors have been previously developed and studied in cancers, including gynecologic malignancies. Research by Xu et al. studied in vitro and in vivo effects of HIF-1 inhibition with both echinomycin and PX-478 to reduce the expression of HIF target genes. Their research demonstrated that both inhibitors were effective in the attenuation of growth and induction of apoptosis of fibroids in vitro and decreased fibroid growth when assessed using in vivo mice models [105]. Echinomycin is a small DNA-binding molecule in the quinoxaline antibiotic family and has been shown to specifically inhibit the activity of HIF-1 and lead to proteasomal degradation of HIF1-alpha [106,107,108]. Similarly, PX-478 is an orally active small molecule that has been shown to inhibit the translation of HIF1-alpha in both hypoxic and normoxic conditions [109]. PX-478 is also being studied in combination with CAR-T cell therapy in cervical cancer pre-clinical models, as potent hypoxic signaling via HIF-1a can decrease CAR-T efficacy [110]. HIF-1α inhibitor KC7F2 reduced TGFβ3 expression in fibroid cell culture, enforcing the cross-talk between these pathways [92]. In other organ systems, multiple clinical trials are underway, attempting to target HIF signaling, and the development of novel agents with specificity for organ systems is an area of ongoing research [111].

6.3. WNT/β-Catenin Inhibition

Simvastatin has been shown to inhibit Wnt signaling in vitro through decreasing Wnt4 expression and expression of co-receptor LRP5. An ongoing double-blind, phase 2, randomized control trial (NCT03400826) is assessing the effect of daily treatment with 3 months of simvastatin prior to hysterectomy/myomectomy for women with fibroids. Post-operative assessment of tissues has shown a significant reduction in the active form of β-catenin, confirming the translational possibility of statin treatment for fibroids [112].
Vitamin D3 has also been studied in many oncologic contexts [113] and has been shown to reduce levels of Wnt4 and β-catenin, decrease expression/activation of mTOR [114], and inhibit TGFβ3 mediated fibrosis [95] in in vitro studies of leiomyoma cells. Multiple population-based association studies have found lower levels of vitamin D to be associated with higher fibroid burdens [115,116,117]. Similarly, methyl jasmonate, a natural cyclopentanone lipid phytohormone and antioxidant, and Resveratrol, a natural polyphenolic phytoalexin, decreased leiomyoma cell growth through inhibiting activation of Wnt/β-catenin signaling [118,119]. Other targets of Wnt signaling, inhibitors of β-catenin and TCF4 (ICAT), niclosamide, and XAV939 have also shown significant anti-proliferative effects on primary cultures of human leiomyoma cells in vitro [120]. Multiple phase 1 and 2 studies of Wnt inhibitors are being conducted in a variety of tumor types but not have yet been approved for study in leiomyoma [121].

6.4. TGFβ Inhibition

GnRH agonists, one of the FDA-approved treatments for fibroids, have antiangiogenic properties and down-regulate TGFβR expression and downstream effects [122]; however, length of use is limited due to safety [123]. Additional studies of inhibition at various points in the TGFβ/Smad pathway have shown decreased fibroid proliferation in vitro via suspected end-target inhibition of ROS generation by NOX4. Specific inhibitory agents showing efficacy included TGFβ/Smad inhibitor SB431542, NOX4 specific inhibitor GLX351322, and HIF-1α inhibitor KC7F2 [24,92,124]. TGFβ inhibition has also been shown to decrease normal myometrial growth, though to a lesser degree than leiomyoma growth, which may be a barrier to the clinical use of these inhibitors [125].

7. Future Directions and Conclusions

Fibroid research continues to provide key insights into hypoxia-induced cell transformation, extracellular matrix pathophysiology, hypoxic cell signaling cascades, and uterine biology. Oxidative stress and subsequent hypoxia have emerged as a driver of fibroid tumorigenesis through (1) promoting myometrial stem cell proliferation, (2) causing DNA damage propelling transformation of stem cells to tumor-initiating cells, and (3) driving excess ECM production. Fibroid growth, persistence, and spread are propagated through hypoxia-triggered cell signaling via various pathways including HIF-1, TGFβ, and Wnt/β-catenin. Hypoxia persists due to fibroid loss of antioxidant function, ECM accumulation, and growth beyond adequate vascular supplies. Current clinically available treatments for fibroids do not take advantage of therapies targeting hypoxia. Growing pre-clinical and clinical studies identify ROS inhibitors, anti-HIF-1 agents, Wnt/β-catenin inhibition, and TGFβ cascade inhibitors as agents that reduce fibroid development and growth through targeting hypoxia.
The National Institutes of Health allocated USD 15 million for fibroid-related research in 2022, putting it in the bottom ninth of 315 diseases receiving funding and allocating a mere USD 0.50 to USD 1.25 per woman affected in the United States [126,127]. Notably, the prevalence of fibroids is 2–3× greater in black and brown women compared to white women [128]. As a matter of health justice, further research and attention need to be given to widening our understanding of treatment modalities for fibroids. Hypoxia-related research and therapeutic targets are one area of interest to continue exploring in fibroids.

Author Contributions

Conceptualization, S.L.O. and M.A.B.; writing—original draft preparation, S.L.O., R.J.A., A.G. and L.I.F.; writing—review and editing, S.L.O., R.J.A., A.G., L.I.F. and M.A.B.; supervision, M.A.B.; funding acquisition, M.A.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded in part by the National Institutes of Health grants R01HD094380 and R01HD111243.

Conflicts of Interest

The authros declare no conflicts of interest.

References

  1. Stewart, E.A.; Cookson, C.L.; Gandolfo, R.A.; Schulze-Rath, R. Epidemiology of Uterine Fibroids: A Systematic Review. BJOG Int. J. Obstet. Gynaecol. 2017, 124, 1501–1512. [Google Scholar] [CrossRef] [PubMed]
  2. Li, B.; Wang, F.; Chen, L.; Tong, H. Global Epidemiological Characteristics of Uterine Fibroids. Arch. Med. Sci. AMS 2023, 19, 1802–1810. [Google Scholar] [CrossRef] [PubMed]
  3. Pritts, E.A.; Parker, W.H.; Olive, D.L. Fibroids and Infertility: An Updated Systematic Review of the Evidence. Fertil. Steril. 2009, 91, 1215–1223. [Google Scholar] [CrossRef] [PubMed]
  4. Haan, Y.C.; Diemer, F.S.; Van Der Woude, L.; Van Montfrans, G.A.; Oehlers, G.P.; Brewster, L.M. The Risk of Hypertension and Cardiovascular Disease in Women with Uterine Fibroids. J. Clin. Hypertens. 2018, 20, 718–726. [Google Scholar] [CrossRef] [PubMed]
  5. Chiuve, S.E.; Huisingh, C.; Petruski-Ivleva, N.; Owens, C.; Kuohung, W.; Wise, L.A. Uterine Fibroids and Incidence of Depression, Anxiety and Self-Directed Violence: A Cohort Study. J. Epidemiol. Community Health 2022, 76, 92–99. [Google Scholar] [CrossRef]
  6. Cardozo, E.R.; Clark, A.D.; Banks, N.K.; Henne, M.B.; Stegmann, B.J.; Segars, J.H. The Estimated Annual Cost of Uterine Leiomyomata in the United States. Am. J. Obstet. Gynecol. 2012, 206, 211-e1–211-e9. [Google Scholar] [CrossRef] [PubMed]
  7. AlAshqar, A.; Lulseged, B.; Mason-Otey, A.; Liang, J.; Begum, U.A.M.; Afrin, S.; Borahay, M.A. Oxidative Stress and Antioxidants in Uterine Fibroids: Pathophysiology and Clinical Implications. Antioxidants 2023, 12, 807. [Google Scholar] [CrossRef] [PubMed]
  8. Sies, H.; Berndt, C.; Jones, D.P. Oxidative Stress. Annu. Rev. Biochem. 2017, 86, 715–748. [Google Scholar] [CrossRef] [PubMed]
  9. Forman, H.J.; Zhang, H. Targeting Oxidative Stress in Disease: Promise and Limitations of Antioxidant Therapy. Nat. Rev. Drug Discov. 2021, 20, 689–709. [Google Scholar] [CrossRef]
  10. Zuo, J.; Zhang, Z.; Luo, M.; Zhou, L.; Nice, E.C.; Zhang, W.; Wang, C.; Huang, C. Redox Signaling at the Crossroads of Human Health and Disease. MedComm 2022, 3, e127. [Google Scholar] [CrossRef]
  11. Tafani, M.; Sansone, L.; Limana, F.; Arcangeli, T.; De Santis, E.; Polese, M.; Fini, M.; Russo, M.A. The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression. Oxid. Med. Cell. Longev. 2015, 2016, e3907147. [Google Scholar] [CrossRef] [PubMed]
  12. Lee, P.; Chandel, N.S.; Simon, M.C. Cellular Adaptation to Hypoxia through Hypoxia Inducible Factors and Beyond. Nat. Rev. Mol. Cell Biol. 2020, 21, 268–283. [Google Scholar] [CrossRef] [PubMed]
  13. Luo, Z.; Tian, M.; Yang, G.; Tan, Q.; Chen, Y.; Li, G.; Zhang, Q.; Li, Y.; Wan, P.; Wu, J. Hypoxia Signaling in Human Health and Diseases: Implications and Prospects for Therapeutics. Signal Transduct. Target. Ther. 2022, 7, 218. [Google Scholar] [CrossRef] [PubMed]
  14. Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative Stress in Cancer. Cancer Cell 2020, 38, 167–197. [Google Scholar] [CrossRef] [PubMed]
  15. Markee, J.E. Menstruation in Intraocular Endometrial Transplants in the Rhesus Monkey. Am. J. Obstet. Gynecol. 1978, 131, 558–559. [Google Scholar] [CrossRef] [PubMed]
  16. Maybin, J.A.; Murray, A.A.; Saunders, P.T.K.; Hirani, N.; Carmeliet, P.; Critchley, H.O.D. Hypoxia and Hypoxia Inducible Factor-1α Are Required for Normal Endometrial Repair during Menstruation. Nat. Commun. 2018, 9, 295. [Google Scholar] [CrossRef]
  17. Cousins, F.L.; Murray, A.A.; Scanlon, J.P.; Saunders, P.T.K. HypoxyprobeTM Reveals Dynamic Spatial and Temporal Changes in Hypoxia in a Mouse Model of Endometrial Breakdown and Repair. BMC Res. Notes 2016, 9, 30. [Google Scholar] [CrossRef] [PubMed]
  18. Reavey, J.J.; Walker, C.; Nicol, M.; Murray, A.A.; Critchley, H.O.D.; Kershaw, L.E.; Maybin, J.A. Markers of Human Endometrial Hypoxia Can Be Detected in Vivo and Ex Vivo during Physiological Menstruation. Hum. Reprod. Oxf. Engl. 2021, 36, 941. [Google Scholar] [CrossRef]
  19. Flake, G.P.; Moore, A.B.; Sutton, D.; Kissling, G.E.; Horton, J.; Wicker, B.; Walmer, D.; Robboy, S.J.; Dixon, D. The Natural History of Uterine Leiomyomas: Light and Electron Microscopic Studies of Fibroid Phases, Interstitial Ischemia, Inanosis, and Reclamation. Obstet. Gynecol. Int. 2013, 2013, 528376. [Google Scholar] [CrossRef]
  20. Yang, Q.; Ciebiera, M.; Bariani, M.V.; Ali, M.; Elkafas, H.; Boyer, T.G.; Al-Hendy, A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr. Rev. 2021, 43, 678–719. [Google Scholar] [CrossRef]
  21. Mayer, A.; Hoeckel, M.; von Wallbrunn, A.; Horn, L.-C.; Wree, A.; Vaupel, P. HIF-Mediated Hypoxic Response Is Missing in Severely Hypoxic Uterine Leiomyomas. Adv. Exp. Med. Biol. 2010, 662, 399–405. [Google Scholar] [CrossRef]
  22. Hou, P.; Zhao, L.; Li, Y.; Luo, F.; Wang, S.; Song, J.; Bai, J. Comparative Expression of Thioredoxin-1 in Uterine Leiomyomas and Myometrium. Mol. Hum. Reprod. 2014, 20, 148–154. [Google Scholar] [CrossRef] [PubMed]
  23. Ishikawa, H.; Xu, L.; Sone, K.; Kobayashi, T.; Wang, G.; Shozu, M. Hypoxia Induces Hypoxia-Inducible Factor 1α and Potential HIF-Responsive Gene Expression in Uterine Leiomyoma. Reprod. Sci. 2019, 26, 428–435. [Google Scholar] [CrossRef] [PubMed]
  24. Miyashita-Ishiwata, M.; El Sabeh, M.; Reschke, L.D.; Afrin, S.; Borahay, M.A. Differential Response to Hypoxia in Leiomyoma and Myometrial Cells. Life Sci. 2022, 290, 120238. [Google Scholar] [CrossRef]
  25. Wallace, K.; Chatman, K.; Porter, J.; Scott, J.; Johnson, V.; Moseley, J.; LaMarca, B. Enodthelin 1 Is Elevated in Plasma and Explants from Patients Having Uterine Leiomyomas. Reprod. Sci. 2014, 21, 1196–1205. [Google Scholar] [CrossRef] [PubMed]
  26. Fletcher, N.M.; Saed, M.G.; Abu-Soud, H.M.; Al-Hendy, A.; Diamond, M.P.; Saed, G.M. Uterine Fibroids Are Characterized by an Impaired Antioxidant Cellular System: Potential Role of Hypoxia in the Pathophysiology of Uterine Fibroids. J. Assist. Reprod. Genet. 2013, 30, 969–974. [Google Scholar] [CrossRef] [PubMed]
  27. Fedotova, M.; Barysheva, E.; Bushueva, O. Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development. Life 2023, 13, 1740. [Google Scholar] [CrossRef] [PubMed]
  28. Ono, M.; Maruyama, T.; Masuda, H.; Kajitani, T.; Nagashima, T.; Arase, T.; Ito, M.; Ohta, K.; Uchida, H.; Asada, H.; et al. Side Population in Human Uterine Myometrium Displays Phenotypic and Functional Characteristics of Myometrial Stem Cells. Proc. Natl. Acad. Sci. USA 2007, 104, 18700–18705. [Google Scholar] [CrossRef] [PubMed]
  29. Prusinski Fernung, L.E.; Al-Hendy, A.; Yang, Q. A Preliminary Study: Human Fibroid Stro-1+/CD44+ Stem Cells Isolated From Uterine Fibroids Demonstrate Decreased DNA Repair and Genomic Integrity Compared to Adjacent Myometrial Stro-1+/CD44+ Cells. Reprod. Sci. 2019, 26, 619–638. [Google Scholar] [CrossRef]
  30. Tubbs, A.; Nussenzweig, A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell 2017, 168, 644–656. [Google Scholar] [CrossRef]
  31. Mas, A.; Nair, S.; Laknaur, A.; Simón, C.; Diamond, M.P.; Al-Hendy, A. Stro-1/CD44 as Putative Human Myometrial and Fibroid Stem Cell Markers. Fertil. Steril. 2015, 104, 225–234.e3. [Google Scholar] [CrossRef]
  32. Chang, H.L.; Senaratne, T.N.; Zhang, L.; Szotek, P.P.; Stewart, E.; Dombkowski, D.; Preffer, F.; Donahoe, P.K.; Teixeira, J. Uterine Leiomyomas Exhibit Fewer Stem/Progenitor Cell Characteristics When Compared with Corresponding Normal Myometrium. Reprod. Sci. 2010, 17, 158–167. [Google Scholar] [CrossRef] [PubMed]
  33. Maruyama, T.; Miyazaki, K.; Masuda, H.; Ono, M.; Uchida, H.; Yoshimura, Y. Review: Human Uterine Stem/Progenitor Cells: Implications for Uterine Physiology and Pathology. Placenta 2013, 34, S68–S72. [Google Scholar] [CrossRef]
  34. Mohyeldin, A.; Garzón-Muvdi, T.; Quiñones-Hinojosa, A. Oxygen in Stem Cell Biology: A Critical Component of the Stem Cell Niche. Cell Stem Cell 2010, 7, 150–161. [Google Scholar] [CrossRef]
  35. Mas, A.; Stone, L.; O’Connor, P.M.; Yang, Q.; Kleven, D.; Simon, C.; Walker, C.L.; Al-Hendy, A. Developmental Exposure to Endocrine Disruptors Expands Murine Myometrial Stem Cell Compartment as a Prerequisite to Leiomyoma Tumorigenesis. Stem Cells 2017, 35, 666–678. [Google Scholar] [CrossRef]
  36. Juan, C.A.; Pérez de la Lastra, J.M.; Plou, F.J.; Pérez-Lebeña, E. The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. Int. J. Mol. Sci. 2021, 22, 4642. [Google Scholar] [CrossRef] [PubMed]
  37. Li, Y.; Xu, X.; Asif, H.; Feng, Y.; Kohrn, B.F.; Kennedy, S.R.; Kim, J.J.; Wei, J.-J. Myometrial Oxidative Stress Drives MED12 Mutations in Leiomyoma. Cell Biosci. 2022, 12, 111. [Google Scholar] [CrossRef]
  38. Ishikawa, H.; Kobayashi, T.; Kaneko, M.; Saito, Y.; Shozu, M.; Koga, K. RISING STARS: Role of MED12 Mutation in the Pathogenesis of Uterine Fibroids. J. Mol. Endocrinol. 2023, 71, e230039. [Google Scholar] [CrossRef] [PubMed]
  39. Mäkinen, N.; Mehine, M.; Tolvanen, J.; Kaasinen, E.; Li, Y.; Lehtonen, H.J.; Gentile, M.; Yan, J.; Enge, M.; Taipale, M.; et al. MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas. Science 2011, 334, 252–255. [Google Scholar] [CrossRef]
  40. Je, E.M.; Kim, M.R.; Min, K.O.; Yoo, N.J.; Lee, S.H. Mutational Analysis of MED12 Exon 2 in Uterine Leiomyoma and Other Common Tumors. Int. J. Cancer 2012, 131, E1044–E1047. [Google Scholar] [CrossRef]
  41. Malik, S.; Roeder, R.G. The Metazoan Mediator Co-Activator Complex as an Integrative Hub for Transcriptional Regulation. Nat. Rev. Genet. 2010, 11, 761–772. [Google Scholar] [CrossRef] [PubMed]
  42. Park, M.J.; Shen, H.; Kim, N.H.; Gao, F.; Failor, C.; Knudtson, J.F.; McLaughlin, J.; Halder, S.K.; Heikkinen, T.A.; Vahteristo, P.; et al. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas. J. Clin. Endocrinol. Metab. 2018, 103, 4283–4292. [Google Scholar] [CrossRef] [PubMed]
  43. Muralimanoharan, S.; Shamby, R.; Stansbury, N.; Schenken, R.; de la Pena Avalos, B.; Javanmardi, S.; Dray, E.; Sung, P.; Boyer, T.G. Aberrant R-Loop-Induced Replication Stress in MED12-Mutant Uterine Fibroids. Sci. Rep. 2022, 12, 6169. [Google Scholar] [CrossRef]
  44. Klatt, F.; Leitner, A.; Kim, I.V.; Ho-Xuan, H.; Schneider, E.V.; Langhammer, F.; Weinmann, R.; Müller, M.R.; Huber, R.; Meister, G.; et al. A Precisely Positioned MED12 Activation Helix Stimulates CDK8 Kinase Activity. Proc. Natl. Acad. Sci. USA 2020, 117, 2894–2905. [Google Scholar] [CrossRef]
  45. Takao, T.; Ono, M.; Yoshimasa, Y.; Masuda, H.; Maruyama, T. A Mediator Complex Subunit 12 Gain-of-Function Mutation Induces Partial Leiomyoma Cell Properties in Human Uterine Smooth Muscle Cells. FS Sci. 2022, 3, 288–298. [Google Scholar] [CrossRef]
  46. El Andaloussi, A.; Al-Hendy, A.; Ismail, N.; Boyer, T.G.; Halder, S.K. Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell. Reprod. Sci. 2020, 27, 823–832. [Google Scholar] [CrossRef] [PubMed]
  47. Maekawa, R.; Sato, S.; Tamehisa, T.; Sakai, T.; Kajimura, T.; Sueoka, K.; Sugino, N. Different DNA Methylome, Transcriptome and Histological Features in Uterine Fibroids with and without MED12 Mutations. Sci. Rep. 2022, 12, 8912. [Google Scholar] [CrossRef]
  48. Heinonen, H.-R.; Pasanen, A.; Heikinheimo, O.; Tanskanen, T.; Palin, K.; Tolvanen, J.; Vahteristo, P.; Sjöberg, J.; Pitkänen, E.; Bützow, R.; et al. Multiple Clinical Characteristics Separate MED12-Mutation-Positive and -Negative Uterine Leiomyomas. Sci. Rep. 2017, 7, 1015. [Google Scholar] [CrossRef] [PubMed]
  49. He, C.; Nelson, W.; Li, H.; Xu, Y.-D.; Dai, X.-J.; Wang, Y.-X.; Ding, Y.-B.; Li, Y.-P.; Li, T. Frequency of MED12 Mutation in Relation to Tumor and Patient’s Clinical Characteristics: A Meta-Analysis. Reprod. Sci. 2022, 29, 357–365. [Google Scholar] [CrossRef]
  50. Lee, M.; Cheon, K.; Chae, B.; Hwang, H.; Kim, H.-K.; Chung, Y.-J.; Song, J.-Y.; Cho, H.-H.; Kim, J.-H.; Kim, M.-R. Analysis of MED12 Mutation in Multiple Uterine Leiomyomas in South Korean Patients. Int. J. Med. Sci. 2018, 15, 124–128. [Google Scholar] [CrossRef]
  51. Rajeswari, M.R.; Jain, A. High-Mobility-Group Chromosomal Proteins, HMGA1 as Potential Tumour Markers. Curr. Sci. 2002, 82, 838–844. [Google Scholar]
  52. Galindo, L.J.; Hernández-Beeftink, T.; Salas, A.; Jung, Y.; Reyes, R.; de Oca, F.M.; Hernández, M.; Almeida, T.A. HMGA2 and MED12 Alterations Frequently Co-Occur in Uterine Leiomyomas. Gynecol. Oncol. 2018, 150, 562–568. [Google Scholar] [CrossRef]
  53. Li, Y.; Qiang, W.; Griffin, B.B.; Gao, T.; Chakravarti, D.; Bulun, S.; Kim, J.J.; Wei, J.-J. HMGA2-Mediated Tumorigenesis through Angiogenesis in Leiomyoma. Fertil. Steril. 2020, 114, 1085–1096. [Google Scholar] [CrossRef] [PubMed]
  54. Griffin, B.B.; Ban, Y.; Lu, X.; Wei, J.-J. Hydropic Leiomyoma: A Distinct Variant of Leiomyoma Closely Related to HMGA2 Overexpression. Hum. Pathol. 2019, 84, 164–172. [Google Scholar] [CrossRef] [PubMed]
  55. Mehine, M.; Kaasinen, E.; Heinonen, H.-R.; Mäkinen, N.; Kämpjärvi, K.; Sarvilinna, N.; Aavikko, M.; Vähärautio, A.; Pasanen, A.; Bützow, R.; et al. Integrated Data Analysis Reveals Uterine Leiomyoma Subtypes with Distinct Driver Pathways and Biomarkers. Proc. Natl. Acad. Sci. USA 2016, 113, 1315–1320. [Google Scholar] [CrossRef] [PubMed]
  56. Helmke, B.M.; Markowski, D.N.; Müller, M.H.; Sommer, A.; Müller, J.; Möller, C.; Bullerdiek, J. HMGA Proteins Regulate the Expression of FGF2 in Uterine Fibroids. Mol. Hum. Reprod. 2011, 17, 135–142. [Google Scholar] [CrossRef]
  57. Mescam, M.; Vinnakota, K.C.; Beard, D.A. Identification of the Catalytic Mechanism and Estimation of Kinetic Parameters for Fumarase. J. Biol. Chem. 2011, 286, 21100–21109. [Google Scholar] [CrossRef]
  58. Sullivan, L.B.; Martinez-Garcia, E.; Nguyen, H.; Mullen, A.R.; Dufour, E.; Sudarshan, S.; Licht, J.D.; Deberardinis, R.J.; Chandel, N.S. The Proto-Oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling. Mol. Cell 2013, 51, 236–248. [Google Scholar] [CrossRef]
  59. Harrison, W.J.; Andrici, J.; Maclean, F.; Madadi-Ghahan, R.; Farzin, M.; Sioson, L.; Toon, C.W.; Clarkson, A.; Watson, N.; Pickett, J.; et al. Fumarate Hydratase-Deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. Am. J. Surg. Pathol. 2016, 40, 599–607. [Google Scholar] [CrossRef]
  60. Wheeler, K.C.; Warr, D.J.; Warsetsky, S.I.; Barmat, L.I. Novel Fumarate Hydratase Mutation in a Family with Atypical Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer. Fertil. Steril. 2016, 105, 144–148. [Google Scholar] [CrossRef]
  61. Alkhrait, S.; Ali, M.; Kertowidjojo, E.; Romero, I.L.; Hathaway, F.; Madueke-Laveaux, O.S. Investigating Fumarate Hydratase-Deficient Uterine Fibroids: A Case Series. J. Clin. Med. 2023, 12, 5436. [Google Scholar] [CrossRef] [PubMed]
  62. Sporn, M.B.; Liby, K.T. NRF2 and Cancer: The Good, the Bad and the Importance of Context. Nat. Rev. Cancer 2012, 12, 564–571. [Google Scholar] [CrossRef] [PubMed]
  63. Ma, Q. Role of Nrf2 in Oxidative Stress and Toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426. [Google Scholar] [CrossRef] [PubMed]
  64. Xiao, Q.; Jiang, Y.; Liu, Q.; Yue, J.; Liu, C.; Zhao, X.; Qiao, Y.; Ji, H.; Chen, J.; Ge, G. Minor Type IV Collagen A5 Chain Promotes Cancer Progression through Discoidin Domain Receptor-1. PLoS Genet. 2015, 11, e1005249. [Google Scholar] [CrossRef] [PubMed]
  65. Wang, D.; Mohammad, M.; Wang, Y.; Tan, R.; Murray, L.S.; Ricardo, S.; Dagher, H.; van Agtmael, T.; Savige, J. The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV A5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations. Kidney Int. Rep. 2017, 2, 739–748. [Google Scholar] [CrossRef] [PubMed]
  66. Nozu, K.; Minamikawa, S.; Yamada, S.; Oka, M.; Yanagita, M.; Morisada, N.; Fujinaga, S.; Nagano, C.; Gotoh, Y.; Takahashi, E.; et al. Characterization of Contiguous Gene Deletions in COL4A6 and COL4A5 in Alport Syndrome-Diffuse Leiomyomatosis. J. Hum. Genet. 2017, 62, 733–735. [Google Scholar] [CrossRef] [PubMed]
  67. Mehine, M.; Kaasinen, E.; Mäkinen, N.; Katainen, R.; Kämpjärvi, K.; Pitkänen, E.; Heinonen, H.-R.; Bützow, R.; Kilpivaara, O.; Kuosmanen, A.; et al. Characterization of Uterine Leiomyomas by Whole-Genome Sequencing. N. Engl. J. Med. 2013, 369, 43–53. [Google Scholar] [CrossRef] [PubMed]
  68. Jamaluddin, M.F.B.; Nahar, P.; Tanwar, P.S. Proteomic Characterization of the Extracellular Matrix of Human Uterine Fibroids. Endocrinology 2018, 159, 2656–2669. [Google Scholar] [CrossRef] [PubMed]
  69. Idowu, B.M.; Ibitoye, B.O. Doppler Sonography of Perifibroid and Intrafibroid Arteries of Uterine Leiomyomas. Obstet. Gynecol. Sci. 2018, 61, 395–403. [Google Scholar] [CrossRef]
  70. Moore, A.B.; Yu, L.; Swartz, C.D.; Zheng, X.; Wang, L.; Castro, L.; Kissling, G.E.; Walmer, D.K.; Robboy, S.J.; Dixon, D. Human Uterine Leiomyoma-Derived Fibroblasts Stimulate Uterine Leiomyoma Cell Proliferation and Collagen Type I Production, and Activate RTKs and TGF Beta Receptor Signaling in Coculture. Cell Commun. Signal. 2010, 8, 10. [Google Scholar] [CrossRef]
  71. Holdsworth-Carson, S.J.; Zhao, D.; Cann, L.; Bittinger, S.; Nowell, C.J.; Rogers, P.A.W. Differences in the Cellular Composition of Small versus Large Uterine Fibroids. Reproduction 2016, 152, 467–480. [Google Scholar] [CrossRef] [PubMed]
  72. Malvasi, A.; Cavallotti, C.; Morroni, M.; Lorenzi, T.; Dell’Edera, D.; Nicolardi, G.; Tinelli, A. Uterine Fibroid Pseudocapsule Studied by Transmission Electron Microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 162, 187–191. [Google Scholar] [CrossRef] [PubMed]
  73. Walocha, J.A.; Litwin, J.A.; Miodoński, A.J. Vascular System of Intramural Leiomyomata Revealed by Corrosion Casting and Scanning Electron Microscopy. Hum. Reprod. 2003, 18, 1088–1093. [Google Scholar] [CrossRef] [PubMed]
  74. Islam, M.S.; Ciavattini, A.; Petraglia, F.; Castellucci, M.; Ciarmela, P. Extracellular Matrix in Uterine Leiomyoma Pathogenesis: A Potential Target for Future Therapeutics. Hum. Reprod. Update 2018, 24, 59–85. [Google Scholar] [CrossRef] [PubMed]
  75. Romero, Y.; Aquino-Gálvez, A. Hypoxia in Cancer and Fibrosis: Part of the Problem and Part of the Solution. Int. J. Mol. Sci. 2021, 22, 8335. [Google Scholar] [CrossRef] [PubMed]
  76. Majora, M.; Wittkampf, T.; Schuermann, B.; Schneider, M.; Franke, S.; Grether-Beck, S.; Wilichowski, E.; Bernerd, F.; Schroeder, P.; Krutmann, J. Functional Consequences of Mitochondrial DNA Deletions in Human Skin Fibroblasts: Increased Contractile Strength in Collagen Lattices Is Due to Oxidative Stress-Induced Lysyl Oxidase Activity. Am. J. Pathol. 2009, 175, 1019–1029. [Google Scholar] [CrossRef] [PubMed]
  77. Kamel, M.; Wagih, M.; Kilic, G.S.; Diaz-Arrastia, C.R.; Baraka, M.A.; Salama, S.A. Overhydroxylation of Lysine of Collagen Increases Uterine Fibroids Proliferation: Roles of Lysyl Hydroxylases, Lysyl Oxidases, and Matrix Metalloproteinases. BioMed Res. Int. 2017, 2017, 5316845. [Google Scholar] [CrossRef] [PubMed]
  78. Arici, A.; Sozen, I. Transforming Growth Factor-Beta3 Is Expressed at High Levels in Leiomyoma Where It Stimulates Fibronectin Expression and Cell Proliferation. Fertil. Steril. 2000, 73, 1006–1011. [Google Scholar] [CrossRef]
  79. Joseph, D.S.; Malik, M.; Nurudeen, S.; Catherino, W.H. Myometrial Cells Undergo Fibrotic Transformation under the Influence of Transforming Growth Factor Beta-3. Fertil. Steril. 2010, 93, 1500–1508. [Google Scholar] [CrossRef]
  80. Navarro, A.; Bariani, M.V.; Yang, Q.; Al-Hendy, A. Understanding the Impact of Uterine Fibroids on Human Endometrium Function. Front. Cell Dev. Biol. 2021, 9, 633180. [Google Scholar] [CrossRef]
  81. Ziello, J.E.; Jovin, I.S.; Huang, Y. Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and Its Potential for Therapeutic Intervention in Malignancy and Ischemia. Yale J. Biol. Med. 2007, 80, 51–60. [Google Scholar] [PubMed]
  82. Corrado, C.; Fontana, S. Hypoxia and HIF Signaling: One Axis with Divergent Effects. Int. J. Mol. Sci. 2020, 21, 5611. [Google Scholar] [CrossRef] [PubMed]
  83. El Sabeh, M.; Saha, S.K.; Afrin, S.; Islam, M.S.; Borahay, M.A. Wnt/β-Catenin Signaling Pathway in Uterine Leiomyoma: Role in Tumor Biology and Targeting Opportunities. Mol. Cell. Biochem. 2021, 476, 3513–3536. [Google Scholar] [CrossRef] [PubMed]
  84. Pai, S.G.; Carneiro, B.A.; Mota, J.M.; Costa, R.; Leite, C.A.; Barroso-Sousa, R.; Kaplan, J.B.; Chae, Y.K.; Giles, F.J. Wnt/Beta-Catenin Pathway: Modulating Anticancer Immune Response. J. Hematol. Oncol. 2017, 10, 101. [Google Scholar] [CrossRef] [PubMed]
  85. El Sabeh, M.; Afrin, S.; Singh, B.; Miyashita-Ishiwata, M.; Borahay, M. Uterine Stem Cells and Benign Gynecological Disorders: Role in Pathobiology and Therapeutic Implications. Stem Cell Rev. Rep. 2021, 17, 803–820. [Google Scholar] [CrossRef] [PubMed]
  86. Ono, M.; Yin, P.; Navarro, A.; Moravek, M.B.; Coon, J.S.; Druschitz, S.A.; Serna, V.A.; Qiang, W.; Brooks, D.C.; Malpani, S.S.; et al. Paracrine Activation of WNT/β-Catenin Pathway in Uterine Leiomyoma Stem Cells Promotes Tumor Growth. Proc. Natl. Acad. Sci. USA 2013, 110, 17053–17058. [Google Scholar] [CrossRef] [PubMed]
  87. Mas, A.; Cervello, I.; Gil-Sanchis, C.; Simón, C. Current Understanding of Somatic Stem Cells in Leiomyoma Formation. Fertil. Steril. 2014, 102, 613–620. [Google Scholar] [CrossRef] [PubMed]
  88. Borahay, M.A.; Al-Hendy, A.; Kilic, G.S.; Boehning, D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol. Med. Camb. Mass 2015, 21, 242–256. [Google Scholar] [CrossRef] [PubMed]
  89. Ciebiera, M.; Włodarczyk, M.; Wrzosek, M.; Męczekalski, B.; Nowicka, G.; Łukaszuk, K.; Ciebiera, M.; Słabuszewska-Jóźwiak, A.; Jakiel, G. Role of Transforming Growth Factor β in Uterine Fibroid Biology. Int. J. Mol. Sci. 2017, 18, 2435. [Google Scholar] [CrossRef]
  90. Malik, M.; Catherino, W.H. Novel Method to Characterize Primary Cultures of Leiomyoma and Myometrium with the Use of Confirmatory Biomarker Gene Arrays. Fertil. Steril. 2007, 87, 1166–1172. [Google Scholar] [CrossRef]
  91. Norian, J.M.; Malik, M.; Parker, C.Y.; Joseph, D.; Leppert, P.C.; Segars, J.H.; Catherino, W.H. Transforming Growth Factor Beta3 Regulates the Versican Variants in the Extracellular Matrix-Rich Uterine Leiomyomas. Reprod. Sci. 2009, 16, 1153–1164. [Google Scholar] [CrossRef]
  92. Miyashita-Ishiwata, M.; El Sabeh, M.; Reschke, L.D.; Afrin, S.; Borahay, M.A. Hypoxia Induces Proliferation via NOX4-Mediated Oxidative Stress and TGF-Β3 Signaling in Uterine Leiomyoma Cells. Free Radic. Res. 2022, 56, 163–172. [Google Scholar] [CrossRef]
  93. Salama, S.A.; Diaz-Arrastia, C.R.; Kilic, G.S.; Kamel, M.W. 2-Methoxyestradiol Causes Functional Repression of Transforming Growth Factor Β3 Signaling by Ameliorating Smad and Non-Smad Signaling Pathways in Immortalized Uterine Fibroid Cells. Fertil. Steril. 2012, 98, 178–184. [Google Scholar] [CrossRef]
  94. Nisimoto, Y.; Diebold, B.A.; Cosentino-Gomes, D.; Lambeth, J.D. Nox4: A Hydrogen Peroxide-Generating Oxygen Sensor. Biochemistry 2014, 53, 5111–5120. [Google Scholar] [CrossRef] [PubMed]
  95. Halder, S.K.; Goodwin, J.S.; Al-Hendy, A. 1,25-Dihydroxyvitamin D3 Reduces TGF-Beta3-Induced Fibrosis-Related Gene Expression in Human Uterine Leiomyoma Cells. J. Clin. Endocrinol. Metab. 2011, 96, E754–E762. [Google Scholar] [CrossRef]
  96. Marklund, S.L. Extracellular Superoxide Dismutase in Human Tissues and Human Cell Lines. J. Clin. Investig. 1984, 74, 1398–1403. [Google Scholar] [CrossRef] [PubMed]
  97. Vidimar, V.; Gius, D.; Chakravarti, D.; Bulun, S.E.; Wei, J.-J.; Kim, J.J. Dysfunctional MnSOD Leads to Redox Dysregulation and Activation of Prosurvival AKT Signaling in Uterine Leiomyomas. Sci. Adv. 2016, 2, e1601132. [Google Scholar] [CrossRef]
  98. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet. Gynecol. 2021, 137, e100–e115. [CrossRef] [PubMed]
  99. Stewart, E.A. Uterine Fibroids. N. Engl. J. Med. 2015, 372, 1646–1655. [Google Scholar] [CrossRef]
  100. Wright, J.D.; Herzog, T.J.; Tsui, J.; Ananth, C.V.; Lewin, S.N.; Lu, Y.-S.; Neugut, A.I.; Hershman, D.L. Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States. Obstet. Gynecol. 2013, 122, 233–241. [Google Scholar] [CrossRef]
  101. Szydłowska, I.; Nawrocka-Rutkowska, J.; Brodowska, A.; Marciniak, A.; Starczewski, A.; Szczuko, M. Dietary Natural Compounds and Vitamins as Potential Cofactors in Uterine Fibroids Growth and Development. Nutrients 2022, 14, 734. [Google Scholar] [CrossRef] [PubMed]
  102. Zhang, D.; Al-Hendy, M.; Richard-Davis, G.; Montgomery-Rice, V.; Rajaratnam, V.; Al-Hendy, A. Antiproliferative and Proapoptotic Effects of Epigallocatechin Gallate on Human Leiomyoma Cells. Fertil. Steril. 2010, 94, 1887–1893. [Google Scholar] [CrossRef] [PubMed]
  103. Borahay, M.A.; Kilic, G.S.; Yallampalli, C.; Snyder, R.R.; Hankins, G.D.V.; Al-Hendy, A.; Boehning, D. Simvastatin Potently Induces Calcium-Dependent Apoptosis of Human Leiomyoma Cells. J. Biol. Chem. 2014, 289, 35075–35086. [Google Scholar] [CrossRef] [PubMed]
  104. Aghaamoo, S.; Zandbina, A.; Saffarieh, E.; Nassiri, S. The Effect of N-Acetyl Cysteine on the Volume of Uterine Leiomyoma: A Randomized Clinical Trial. Int. J. Gynecol. Obstet. 2021, 154, 521–525. [Google Scholar] [CrossRef] [PubMed]
  105. Xu, L.; Ishikawa, H.; Zhou, Y.; Kobayashi, T.; Shozu, M. Antitumor Effect of the Selective Hypoxia-Inducible Factor-1 Inhibitors Echinomycin and PX-478 on Uterine Fibroids. FS Sci. 2022, 3, 187–196. [Google Scholar] [CrossRef] [PubMed]
  106. Kong, D.; Park, E.J.; Stephen, A.G.; Calvani, M.; Cardellina, J.H.; Monks, A.; Fisher, R.J.; Shoemaker, R.H.; Melillo, G. Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity. Cancer Res. 2005, 65, 9047–9055. [Google Scholar] [CrossRef] [PubMed]
  107. Huang, X.; Liu, Y.; Wang, Y.; Bailey, C.; Zheng, P.; Liu, Y. Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma. Cancers 2021, 13, 694. [Google Scholar] [CrossRef] [PubMed]
  108. Chen, J.; Lin, Z.; Song, J.; Plaisance-Bonstaff, K.; James, J.; Mu, S.; Post, S.R.; Dai, L.; Qin, Z. Echinomycin as a Promising Therapeutic Agent against KSHV-Related Malignancies. J. Hematol. Oncol. 2023, 16, 48. [Google Scholar] [CrossRef]
  109. Koh, M.Y.; Spivak-Kroizman, T.; Venturini, S.; Welsh, S.; Williams, R.R.; Kirkpatrick, D.L.; Powis, G. Molecular Mechanisms for the Activity of PX-478, an Antitumor Inhibitor of the Hypoxia-Inducible Factor-1alpha. Mol. Cancer Ther. 2008, 7, 90–100. [Google Scholar] [CrossRef]
  110. Panahi Meymandi, A.R.; Akbari, B.; Soltantoyeh, T.; Shahosseini, Z.; Hosseini, M.; Hadjati, J.; Mirzaei, H.R. PX-478, an HIF-1α Inhibitor, Impairs mesoCAR T Cell Antitumor Function in Cervical Cancer. Front. Oncol. 2024, 14, 1357801. [Google Scholar] [CrossRef]
  111. Lee, J.W.; Ko, J.; Ju, C.; Eltzschig, H.K. Hypoxia Signaling in Human Diseases and Therapeutic Targets. Exp. Mol. Med. 2019, 51, 1–13. [Google Scholar] [CrossRef] [PubMed]
  112. El Sabeh, M.; Saha, S.K.; Afrin, S.; Borahay, M.A. Simvastatin Inhibits Wnt/β-Catenin Pathway in Uterine Leiomyoma. Endocrinology 2021, 162, bqab211. [Google Scholar] [CrossRef]
  113. Seraphin, G.; Rieger, S.; Hewison, M.; Capobianco, E.; Lisse, T.S. The Impact of Vitamin D on Cancer: A Mini Review. J. Steroid Biochem. Mol. Biol. 2023, 231, 106308. [Google Scholar] [CrossRef] [PubMed]
  114. Al-Hendy, A.; Diamond, M.P.; Boyer, T.G.; Halder, S.K. Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. J. Clin. Endocrinol. Metab. 2016, 101, 1542–1551. [Google Scholar] [CrossRef] [PubMed]
  115. Baird, D.D.; Hill, M.C.; Schectman, J.M.; Hollis, B.W. Vitamin d and the Risk of Uterine Fibroids. Epidemiol. Camb. Mass 2013, 24, 447–453. [Google Scholar] [CrossRef]
  116. Paffoni, A.; Somigliana, E.; Vigano’, P.; Benaglia, L.; Cardellicchio, L.; Pagliardini, L.; Papaleo, E.; Candiani, M.; Fedele, L. Vitamin D Status in Women with Uterine Leiomyomas. J. Clin. Endocrinol. Metab. 2013, 98, E1374–E1378. [Google Scholar] [CrossRef] [PubMed]
  117. Sabry, M.; Halder, S.K.; Allah, A.S.A.; Roshdy, E.; Rajaratnam, V.; Al-Hendy, A. Serum Vitamin D3 Level Inversely Correlates with Uterine Fibroid Volume in Different Ethnic Groups: A Cross-Sectional Observational Study. Int. J. Womens Health 2013, 5, 93–100. [Google Scholar] [CrossRef] [PubMed]
  118. Ali, M.; Stone, D.; Laknaur, A.; Yang, Q.; Al-Hendy, A. EZH2 Activates Wnt/β-Catenin Signaling in Human Uterine Fibroids, Which Is Inhibited by the Natural Compound Methyl Jasmonate. FS Sci. 2023, 4, 239–256. [Google Scholar] [CrossRef] [PubMed]
  119. Chen, H.-Y.; Lin, P.-H.; Shih, Y.-H.; Wang, K.-L.; Hong, Y.-H.; Shieh, T.-M.; Huang, T.-C.; Hsia, S.-M. Natural Antioxidant Resveratrol Suppresses Uterine Fibroid Cell Growth and Extracellular Matrix Formation In Vitro and In Vivo. Antioxidants 2019, 8, 99. [Google Scholar] [CrossRef]
  120. Ono, M.; Yin, P.; Navarro, A.; Moravek, M.B.; Coon, V.J.S.; Druschitz, S.A.; Gottardi, C.J.; Bulun, S.E. Inhibition of Canonical WNT Signaling Attenuates Human Leiomyoma Cell Growth. Fertil. Steril. 2014, 101, 1441–1449.e1. [Google Scholar] [CrossRef]
  121. Pećina-Šlaus, N.; Aničić, S.; Bukovac, A.; Kafka, A. Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. Int. J. Mol. Sci. 2023, 24, 6733. [Google Scholar] [CrossRef]
  122. Chegini, N.; Luo, X.; Ding, L.; Ripley, D. The Expression of Smads and Transforming Growth Factor Beta Receptors in Leiomyoma and Myometrium and the Effect of Gonadotropin Releasing Hormone Analogue Therapy. Mol. Cell. Endocrinol. 2003, 209, 9–16. [Google Scholar] [CrossRef]
  123. Hodgson, R.; Bhave Chittawar, P.; Farquhar, C. GnRH Agonists for Uterine Fibroids. Cochrane Database Syst. Rev. 2017, 2017, CD012846. [Google Scholar] [CrossRef]
  124. Narita, T.; Yin, S.; Gelin, C.F.; Moreno, C.S.; Yepes, M.; Nicolaou, K.C.; Van Meir, E.G. Identification of a Novel Small Molecule HIF-1alpha Translation Inhibitor. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009, 15, 6128–6136. [Google Scholar] [CrossRef] [PubMed]
  125. Park, J.Y.; Chae, B.; Kim, M.-R. The Potential of Transforming Growth Factor-Beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma. Int. J. Med. Sci. 2022, 19, 1779–1786. [Google Scholar] [CrossRef] [PubMed]
  126. Marsh, E.E.; Al-Hendy, A.; Kappus, D.; Galitsky, A.; Stewart, E.A.; Kerolous, M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J. Women’s Health 2018, 27, 1359. [Google Scholar] [CrossRef]
  127. Hartmann, K.E.; Fonnesbeck, C.; Surawicz, T.; Krishnaswami, S.; Andrews, J.C.; Wilson, J.E.; Velez-Edwards, D.; Kugley, S.; Sathe, N.A. Evidence Summary. In Management of Uterine Fibroids [Internet]; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2017. [Google Scholar]
  128. Marshall, L.M.; Spiegelman, D.; Barbieri, R.L.; Goldman, M.B.; Manson, J.E.; Colditz, G.A.; Willett, W.C.; Hunter, D.J. Variation in the Incidence of Uterine Leiomyoma among Premenopausal Women by Age and Race. Obstet. Gynecol. 1997, 90, 967–973. [Google Scholar] [CrossRef]
Oxygen 04 00013 g001
Figure 1. Mechanisms of hypoxia in the development of uterine fibroids. In low oxygen environments (indicated by figure details to the right of the downward arrow), hypoxic conditions activate myometrial stem cells (MSCs) (yellow cell) proliferation (top box). Hypoxia induces DNA damage through various mechanisms including single and double-stranded DNA breaks, nitrogen base damage, mismatched bases, and base degradation (middle box). All these mechanisms of DNA damage have the ability to cause genetic alterations, transforming MSCs into tumor-initiating stem cells. Extracellular matrix normally contains collagen (tricolored bundle), fibronectin (green), proteoglycans (grey), and laminins (pink) between smooth muscle myometrial cells (red cell) and MSCs (yellow cell). Hypoxia induces increased ECM production through increased synthesis of ECM components as well as increased activity of enzymes that modify the ECM, increasing the number of cross-links and stiffness (bottom box). Fibroblast cell types (dark pink cells) also contribute to fibrosis of the ECM under hypoxic conditions.
Figure 1. Mechanisms of hypoxia in the development of uterine fibroids. In low oxygen environments (indicated by figure details to the right of the downward arrow), hypoxic conditions activate myometrial stem cells (MSCs) (yellow cell) proliferation (top box). Hypoxia induces DNA damage through various mechanisms including single and double-stranded DNA breaks, nitrogen base damage, mismatched bases, and base degradation (middle box). All these mechanisms of DNA damage have the ability to cause genetic alterations, transforming MSCs into tumor-initiating stem cells. Extracellular matrix normally contains collagen (tricolored bundle), fibronectin (green), proteoglycans (grey), and laminins (pink) between smooth muscle myometrial cells (red cell) and MSCs (yellow cell). Hypoxia induces increased ECM production through increased synthesis of ECM components as well as increased activity of enzymes that modify the ECM, increasing the number of cross-links and stiffness (bottom box). Fibroblast cell types (dark pink cells) also contribute to fibrosis of the ECM under hypoxic conditions.
Oxygen 04 00013 g001
Oxygen 04 00013 g002
Figure 2. Cellular mechanisms of the common genetic mutations in leiomyomas. (A) MED12 missense mutation: Mediator of RNA polymerase II transcription, subunit 12 homolog (MED12) normally acts as one of up to 30 proteins to form the mediator complex (purple protein) that modulates RNA polymerase activity through multiple mechanisms. MED12 directly interacts with Cyclin C (CycC) and cyclin-dependent kinase 8 (CDK8) to maintain mediator activity. Wild-type MED12 is associated with TGFβR inhibition. When mutated, MED12 exhibits a gain of function features in fibroids. Downstream effects include (1) increased collaged and extracellular matrix (ECM) production and (2) increased WNT expression and signaling through Frizzled family receptor (FZD), resulting in the accumulation of β-catenin. β-catenin translocates to the nucleus, binds T-cell factor (TCF), and upregulates genes involved in cell growth. (3) Increased expression of pro-growth and fibrotic signal cascade transforming growth factor β (TGFβ) and (4) increased signaling through mechanistic target of rapamycin (mTOR) which inhibits autophagy in fibroids. (B) HMGA2 overexpression: high mobility group AT-hook 2 (HMGA2) binds to AT-rich DNA sequences to maintain chromatin structure and regulate transcription. Overexpression of HMGA2 results in increased expression of downstream targets including proto-oncogene pleomorphic adenoma gene 1 (PLAG1), insulin-like growth factor-2 mRNA-binding proteins 2 (IGF2BP2), insulin-like growth factor-2 (IGF2), prolactin (PRL), prolactin-releasing hormone receptor (PRLHR), fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), transforming growth factor α (TGFα), and vascular endothelial growth factor (VEGF). (C) FH loss of function: fumarate hydratase (FH) converts fumarate to malate as one step in the tricarboxylic acid (TCA) cycle of aerobic metabolism. Deficiencies in FH lead to a buildup of fumarate, which directly binds to the antioxidant glutathione. Glutathione peroxidase (GP) catalyzes the reduction in hydrogen peroxide (H2O2) to water (H2O) and the oxidation of glutathione (GSH) to glutathione disulfide (GSSG); deficient quantities of GST lead to accumulation of ROS. (D) COL4A5/COL4A6 microdeletion/rearrangement: COL4A5 and COL4A6 are alpha chains of type IV collagens that contribute to the structure of the fibroid ECM. When microdeletions and rearrangements in these genes occur, a downstream sequence encoding insulin-receptor substrate 4 (IRS4) is upregulated. IRS4 contributes to increased insulin-like growth factor I (IGF-1), which is known to contribute to uterine fibroid development and growth. Prolactin and COL4A5 are also significantly increased in collagen-mutated fibroids compared to other mutation types and to normal myometrial cells.
Figure 2. Cellular mechanisms of the common genetic mutations in leiomyomas. (A) MED12 missense mutation: Mediator of RNA polymerase II transcription, subunit 12 homolog (MED12) normally acts as one of up to 30 proteins to form the mediator complex (purple protein) that modulates RNA polymerase activity through multiple mechanisms. MED12 directly interacts with Cyclin C (CycC) and cyclin-dependent kinase 8 (CDK8) to maintain mediator activity. Wild-type MED12 is associated with TGFβR inhibition. When mutated, MED12 exhibits a gain of function features in fibroids. Downstream effects include (1) increased collaged and extracellular matrix (ECM) production and (2) increased WNT expression and signaling through Frizzled family receptor (FZD), resulting in the accumulation of β-catenin. β-catenin translocates to the nucleus, binds T-cell factor (TCF), and upregulates genes involved in cell growth. (3) Increased expression of pro-growth and fibrotic signal cascade transforming growth factor β (TGFβ) and (4) increased signaling through mechanistic target of rapamycin (mTOR) which inhibits autophagy in fibroids. (B) HMGA2 overexpression: high mobility group AT-hook 2 (HMGA2) binds to AT-rich DNA sequences to maintain chromatin structure and regulate transcription. Overexpression of HMGA2 results in increased expression of downstream targets including proto-oncogene pleomorphic adenoma gene 1 (PLAG1), insulin-like growth factor-2 mRNA-binding proteins 2 (IGF2BP2), insulin-like growth factor-2 (IGF2), prolactin (PRL), prolactin-releasing hormone receptor (PRLHR), fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), transforming growth factor α (TGFα), and vascular endothelial growth factor (VEGF). (C) FH loss of function: fumarate hydratase (FH) converts fumarate to malate as one step in the tricarboxylic acid (TCA) cycle of aerobic metabolism. Deficiencies in FH lead to a buildup of fumarate, which directly binds to the antioxidant glutathione. Glutathione peroxidase (GP) catalyzes the reduction in hydrogen peroxide (H2O2) to water (H2O) and the oxidation of glutathione (GSH) to glutathione disulfide (GSSG); deficient quantities of GST lead to accumulation of ROS. (D) COL4A5/COL4A6 microdeletion/rearrangement: COL4A5 and COL4A6 are alpha chains of type IV collagens that contribute to the structure of the fibroid ECM. When microdeletions and rearrangements in these genes occur, a downstream sequence encoding insulin-receptor substrate 4 (IRS4) is upregulated. IRS4 contributes to increased insulin-like growth factor I (IGF-1), which is known to contribute to uterine fibroid development and growth. Prolactin and COL4A5 are also significantly increased in collagen-mutated fibroids compared to other mutation types and to normal myometrial cells.
Oxygen 04 00013 g002
Oxygen 04 00013 g003
Figure 3. Emerging therapeutics targeting hypoxia and reactive oxygen species for treatment of uterine fibroids. (1) Targeted inhibition of ROS in leiomyoma has been shown through antioxidant-rich diets, N-acetyl cysteine (NAC), and the use of statins. (2) Hypoxia-inducible factor 1 (HIF-1) is activated by (forward arrow) hypoxia and ROS. PX-478 and KC752 both inhibit (flat line marker) pathways upstream of HIF-1α, resulting in lower concentrations of HIF-1α and reduced cell growth of leiomyoma cells. HIF-1α translocates to the nucleus under hypoxic conditions and binds with HIF-1β, which permanently resides in the nucleus. The heterodimer locates and associates with hypoxia-responsive elements (HREs) of its target genes, resulting in transcriptional upregulation of genes involved in angiogenesis, proliferation, and anti-apoptotic pathways, all of which can contribute to further hypoxia (symbolized by red arrow O2) and ROS. Echinomycin inhibits the ability of HIF-1a to bind DNA. (3) Wingless-related integration site/β-catenin (Wnt/β-catenin) also drives fibroid growth and results in further hypoxia given the dysregulated proliferation. Wnt is secreted into the ECM and activates the Frizzled family receptor (FZD) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). Downstream of this receptor, activation of β-catenin accumulates in the cytoplasm and then translocates to the nucleus and binds T-cell factor (TCF) and lymphocyte enhancement factor (LEF) transcription factors, resulting in upregulation of proteins related to proliferation, cellular differentiation, anti-apoptosis, and TGFβ activation. Methyl jasmonate (MJ) and vitamin D (VitD) both inhibit Wnt expression and signaling through FZD. Resveratrol (RSV) and niclosamide both decrease concentrations of β-catenin. (4) TGFβ inhibition presents a further pathway to target hypoxia drivers. TGFβ3 is directly upregulated under hypoxic conditions and signals through the TGFβR and subsequent activation of SMAD3. Phosphorylated SMAD3 binds phospho-SMAD2 and SMAD4, permitting translocation into the nucleus and binding to SMAD binding elements (SBEs), which increase NADPH oxidase 4 (NOX4), ECM-related proteins, and cellular proliferation. NOX4 directly produces ROS superoxide and H2O2. SB431542 and vitamin D both inhibit the TGFβ3 signal activity. Gonadotropin hormone-releasing hormone (GnRH) agonists down-regulate TGFβR expression. GLX351322 directly inhibits NOX4.
Figure 3. Emerging therapeutics targeting hypoxia and reactive oxygen species for treatment of uterine fibroids. (1) Targeted inhibition of ROS in leiomyoma has been shown through antioxidant-rich diets, N-acetyl cysteine (NAC), and the use of statins. (2) Hypoxia-inducible factor 1 (HIF-1) is activated by (forward arrow) hypoxia and ROS. PX-478 and KC752 both inhibit (flat line marker) pathways upstream of HIF-1α, resulting in lower concentrations of HIF-1α and reduced cell growth of leiomyoma cells. HIF-1α translocates to the nucleus under hypoxic conditions and binds with HIF-1β, which permanently resides in the nucleus. The heterodimer locates and associates with hypoxia-responsive elements (HREs) of its target genes, resulting in transcriptional upregulation of genes involved in angiogenesis, proliferation, and anti-apoptotic pathways, all of which can contribute to further hypoxia (symbolized by red arrow O2) and ROS. Echinomycin inhibits the ability of HIF-1a to bind DNA. (3) Wingless-related integration site/β-catenin (Wnt/β-catenin) also drives fibroid growth and results in further hypoxia given the dysregulated proliferation. Wnt is secreted into the ECM and activates the Frizzled family receptor (FZD) and co-receptor low-density lipoprotein receptor-related protein 5 (LRP5). Downstream of this receptor, activation of β-catenin accumulates in the cytoplasm and then translocates to the nucleus and binds T-cell factor (TCF) and lymphocyte enhancement factor (LEF) transcription factors, resulting in upregulation of proteins related to proliferation, cellular differentiation, anti-apoptosis, and TGFβ activation. Methyl jasmonate (MJ) and vitamin D (VitD) both inhibit Wnt expression and signaling through FZD. Resveratrol (RSV) and niclosamide both decrease concentrations of β-catenin. (4) TGFβ inhibition presents a further pathway to target hypoxia drivers. TGFβ3 is directly upregulated under hypoxic conditions and signals through the TGFβR and subsequent activation of SMAD3. Phosphorylated SMAD3 binds phospho-SMAD2 and SMAD4, permitting translocation into the nucleus and binding to SMAD binding elements (SBEs), which increase NADPH oxidase 4 (NOX4), ECM-related proteins, and cellular proliferation. NOX4 directly produces ROS superoxide and H2O2. SB431542 and vitamin D both inhibit the TGFβ3 signal activity. Gonadotropin hormone-releasing hormone (GnRH) agonists down-regulate TGFβR expression. GLX351322 directly inhibits NOX4.
Oxygen 04 00013 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Olson, S.L.; Akbar, R.J.; Gorniak, A.; Fuhr, L.I.; Borahay, M.A. Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities. Oxygen 2024, 4, 236-252. https://doi.org/10.3390/oxygen4020013

AMA Style

Olson SL, Akbar RJ, Gorniak A, Fuhr LI, Borahay MA. Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities. Oxygen. 2024; 4(2):236-252. https://doi.org/10.3390/oxygen4020013

Chicago/Turabian Style

Olson, Sydney L., Razeen J. Akbar, Adrianna Gorniak, Laura I. Fuhr, and Mostafa A. Borahay. 2024. "Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities" Oxygen 4, no. 2: 236-252. https://doi.org/10.3390/oxygen4020013

Article Metrics

Back to TopTop